- Home
- MYGN vs PFN Comparison
MYGN vs PFN Comparison
Compare MYGN & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PFN
- Stock Information
- Founded
- MYGN 1991
- PFN 2004
- Country
- MYGN United States
- PFN United States
- Employees
- MYGN N/A
- PFN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PFN Finance/Investors Services
- Sector
- MYGN Health Care
- PFN Finance
- Exchange
- MYGN Nasdaq
- PFN Nasdaq
- Market Cap
- MYGN 642.0M
- PFN 692.7M
- IPO Year
- MYGN 1995
- PFN N/A
- Fundamental
- Price
- MYGN $7.40
- PFN $7.58
- Analyst Decision
- MYGN Hold
- PFN
- Analyst Count
- MYGN 13
- PFN 0
- Target Price
- MYGN $13.50
- PFN N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- PFN 331.7K
- Earning Date
- MYGN 11-06-2025
- PFN 01-01-0001
- Dividend Yield
- MYGN N/A
- PFN 11.66%
- EPS Growth
- MYGN N/A
- PFN N/A
- EPS
- MYGN N/A
- PFN N/A
- Revenue
- MYGN $832,900,000.00
- PFN N/A
- Revenue This Year
- MYGN $0.17
- PFN N/A
- Revenue Next Year
- MYGN $6.19
- PFN N/A
- P/E Ratio
- MYGN N/A
- PFN N/A
- Revenue Growth
- MYGN 3.83
- PFN N/A
- 52 Week Low
- MYGN $3.76
- PFN $5.94
- 52 Week High
- MYGN $29.30
- PFN $7.58
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- PFN 49.85
- Support Level
- MYGN $7.13
- PFN $7.57
- Resistance Level
- MYGN $7.80
- PFN $7.67
- Average True Range (ATR)
- MYGN 0.44
- PFN 0.05
- MACD
- MYGN 0.04
- PFN -0.01
- Stochastic Oscillator
- MYGN 78.61
- PFN 20.83
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.